Vorinostat in patients with resistant BRAF^V600E mutated advanced melanoma: a proof of concept study

Papers of special note have been highlighted as: • of interest

References

• 1. ECIS – European Cancer Information System. European Cancer Information System (2019). http://ecis.jrc.ec.europa.eu/explorer
  Google Scholar
• 2. Wolter K. Molecularly targeted therapies for metastatic melanoma (2019). www.uptodate.com
  Google Scholar
• 3. Zia Y, Chen L, Daud A. Future of combination therapy with dabrafenib and trametinib in metastatic melanoma. Expert. Opin. Pharmacother. 16(14), 2257–2263 (2015). • Review highlighting the pharmacology, efficacy and toxicity of clinical trials with dabrafenib and trametinib in patients with BRAFV600E mutant melanoma. Half of the melanoma harbor a BRAFV600E mutation. A major problem of combined dabrafenib and trametinib is the development of resistant, mainly caused by secondary mutations in the MAPK pathway.
  MedlineGoogle Scholar
• 4. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507–2516 (2011).
  Medline CASGoogle Scholar
• 5. Sosman JA, Kim KB, Schuchter L et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366(8), 707–714 (2012).
  Medline CASGoogle Scholar
• 6. Werkgroep NM. Concept richtlijn melanoom (2012). www.oncoline.nl/uploaded/docs/melanoom/CONCEPT%20richtlijn%20melanoom.doc.pdf
  Google Scholar
• 7. Long GV, Hauschild A, Santinami M et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. med. 377(19), 1813–1823 (2017).
  Medline CASGoogle Scholar
• 8. Michielin O, Hoeller C. Gaining momentum: new options and opportunities for the treatment of advanced melanoma. Cancer Treat. Rev. 41(8), 660–670 (2015).
  Medline CASGoogle Scholar
• 9. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 468(7326), 973–977 (2010).
  Medline CASGoogle Scholar
• 10. Wang L, Leite De Oliveira R, Huijberts S et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential. Cell. 173(6), 1413–1425.e1414 (2018). • Resistance to BRAF and MEK inhibitors in BRAFV600E mutant melanoma is associated with increased levels of reactive oxygen species. Treating drug-resistant cells with the histone deacetylase inhibitor vorinostat results in an upregulation of the already high reactive oxygen species levels and leads to cell death. This has been confirmed in mice. In a study in patients, it was found that vorinostat selectivily purged out the resistant tumor clones harboring secondary mutations in the MAPK pathway.
  Medline CASGoogle Scholar
• 11. Scholtens A, Geukes Foppen MH, Blank CU, Van Thienen JV, Van Tinteren H, Haanen JB. Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. Eur. J. cancer. 51(5), 642–652 (2015).
  Medline CASGoogle Scholar
• 12. Sun C, Hobor S, Bertotti A et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell Rep. 7(1), 86–93 (2014).
  Medline CASGoogle Scholar
• 13. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 7, 47–60 (2013).
  Medline CASGoogle Scholar
• 14. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol. 6(6), 637–656 (2012).
  Medline CASGoogle Scholar
• 15. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27(32), 5459–5468 (2009).
  Medline CASGoogle Scholar
• 16. US FDA. FDA approval Zolinza (vorinostat); prescribing information (2008).
  Google Scholar
• 17. Groenendijk FH, De Jong J, Fransen Van De Putte EE et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur. Urol. 69(3), 384–388 (2016).
  Medline CASGoogle Scholar
• 18. Schreuer M, Jansen Y, Planken S et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, Phase 2 clinical trial. Lancet Oncol. 18(4), 464–472 (2017).
  Medline CASGoogle Scholar
• 19. Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother. Pharmacol. 72(3), 493–508 (2013).
  Medline CASGoogle Scholar
• 20. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 21. Gray ES, Rizos H, Reid AL et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget 6(39), 42008–42018 (2015). • Circulating Tumor DNA is a non-invasive method to assess genetic changes during anti-cancer therapy. In 35 of the 48 patients with metastatic melanoma was circulating tumor DNA measurable. ctDNA levels lowered in response to treatment and a NRAS mutation, which might cause resistance to BRAF inhibitors, was detected in 43% of the patients. These data demonstrate that ctDNA is a valuable biomarker to monitor response on targeted therapies.
  MedlineGoogle Scholar
• 22. Calapre L, Warburton L, Millward M, Ziman M, Gray ES. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 404, 62–69 (2017).
  Medline CASGoogle Scholar
• 23. Tsao SC, Weiss J, Hudson C et al. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations. Sci. Rep. 5, 11198 (2015).
  MedlineGoogle Scholar
• 24. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923–3931 (2005). • In this Phase I study, 73 patients with solid tumors were treated with different doses of vorinostat orally. Vorinostat could be safely administered in these patients. Pharmacokinetics were linear and pharmacodynamic analyses showed inhibition of histone deacetylase in peripheral-blood mononuclear cells.
  Medline CASGoogle Scholar
• 25. Fujiwara Y, Yamamoto N, Yamada Y et al. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Sci. 100(9), 1728–1734 (2009).
  Medline CASGoogle Scholar
• 26. Ramalingam SS, Kummar S, Sarantopoulos J et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J. Clin. Oncol. 28(29), 4507–4512 (2010).
  Medline CASGoogle Scholar
• 27. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9(10 Pt 1), 3578–3588 (2003).
  Medline CASGoogle Scholar
• 28. Doi T, Hamaguchi T, Shirao K et al. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial. Int. J. Clin. Oncol. 18(1), 87–95 (2013).
  Medline CASGoogle Scholar
• 29. Atkinson V. Recent advances in malignant melanoma. Intern. Med. J. 47(10), 1114–1121 (2017).
  MedlineGoogle Scholar
• 30. Yu C, Liu X, Yang J et al. Combination of immunotherapy with targeted therapy: theory and practice in metastatic melanoma. Front. Immunol. 10, 990 (2019).
  Medline CASGoogle Scholar
• 31. Geskin L, Malone DC. An exploratory cost-effectiveness analysis of systemic treatments for cutaneous T-cell lymphoma. J. Dermatol. Treat. 29(5), 522–530 (2018).
  Medline CASGoogle Scholar
• 32. Delord JP, Robert C, Nyakas M et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin. Cancer Res. 23(18), 5339–5348 (2017).
  Medline CASGoogle Scholar
• 33. Bendell JC, Javle M, Bekaii-Saab TS et al. A Phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Br. J. Cancer. 116(5), 575–583 (2017).
  Medline CASGoogle Scholar